<Project Title> < [Early Stage OR Later Stage] > <

slide1. <Project Title>< [Early Stage OR Later Stage] >< [PRIP Priority Area] >< [Area of Strategic Priority Innovation (SPI) if applicable] >< Academic collaboration: [Institute | PI] (if any) > <Applicant Company Name><PRIP Project ID> LOGO<br>
slide2. Instructions to fill the project executive summary Use Aptos as the font for all slides. Minimum font size should be:
Title slides - 32 pts
Body text - 14 pts (16+ pts preferred)
Charts and tables - 12 pts (14+ pts preferred)
Do not exceed the boundaries of each slide, ensure text and visuals stay within margins.
Follow the provided template format, avoid changing slide layout, or structure.
Please keep the prompts questions on each page unchanged. Text is grey is suggestive in nature and must be replaced with information relevant to your project.
Information included must match the application form submitted on the PRIP portal. Any inconsistency or false declaration in the executive summary can lead to disqualification from the scheme.
Applicants may, at their discretion, choose to redact any information that they deem confidential
Use the appendix section (if needed) for additional visuals, charts, or references, keep it relevant and concise
Focus on clear, factual descriptions that demonstrate technical merit, regulatory readiness, commercial strategy, & benefit to India.
Do not use promotional language, keep tone professional, specific, and consistent with supporting evidence
Final Review and Submission:
Check formatting, alignment, and spelling before submission.
Save as PDF: Titled in the format: PRIP_<ProjectID>_ Project Presentation.pdf<br>
slide3. Problem and Opportunity Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project. Describe the problem/unmet need proposal tries to address Burden & gap: [Disease/condition] affects [X lakh] Indians/year; [Y%] lack effective options; OOPE ≈ ₹[ ] crore. Source: [ ]
System impact: [e.g., productivity loss, supply fragility] quantified at ₹[ ] crore / [ ] days lost. Source: [ ]
Import dependency (if relevant): [ ]% of [product/component] imported; key bottlenecks: [ ]
SPI (if claimed): Maps to [SPI area] with low market potential but high public-health value. (One line.) Describe the scale and significance of opportunity Describe Impact thesis: [2–3 quantified outcomes] (e.g., −[ ]% mortality; −[ ]% treatment cost; +[ ]% adherence)
“The global market for [specific condition/use case] is ₹. Y crores, growing at a CAGR of Z%.”
“We are targeting [geographies/populations] worth ₹. Z crores.”
"Affects ~720 lakh Indians (Source: ZZ)"
"67% of patients do not meet BB control targets despite therapy"
"There will be significant economic benefits (estimated to be ₹. XXX) arising from this opportunity"<br>
slide4. Solution Overview and Intended Use Describe the product or technology being developed “Our solution, [product name], is a [drug/device/platform] designed for [indication or use] with the goal of [e.g., reducing side effects / improving precision / enabling remote access].”
Design & core mechanism: [1–2 lines]
“It addresses the unmet need by offering [e.g., better dosing precision / improved patient compliance / real-time feedback].” Describe how the product compares to the current standard of care “The current standard involves [brief SoC description], which has limitations such as [e.g., low efficacy, high costs, invasive administration].”
“This solution aims to overcome these through [key feature, e.g., a closed-loop delivery mechanism / AI-based analysis / non-invasive design].”
“This proposal has been submitted under [Early Stage / Later Stage] category and is expected to deliver measurable improvements in [e.g., sensitivity, safety, patient adherence].” Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide5. Technical Readiness and Progress Describe the TRL stage completed and evidence available “The project has completed TRL [X], demonstrated through [e.g., in-vitro assays / animal models / design freeze and test results].”
“Supporting evidence includes [e.g., validation reports, bench testing results, ethics approvals, patent filings].”
“Test license status: [Granted / Under Review / Not Required] as per CDSCO guidelines.”
Please describe current infrastructure at your premise to support the progress so far and activities planned Describe the technical advancement of the proposed solution Quant improvement(s): [ ]% vs [comparator]; method: [protocol / sample size].
“The product delivers technical improvements over current solutions via [e.g., novel formulation, delivery system, sensor technology, software innovation].”
“Compared to competing technologies, our product offers [quantified performance: e.g., 2x detection rate / 30% cost reduction / 50% reduction in power consumption].”
Please describe evidence generated supporting your claims Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide6. Competitive landscape - benchmarking Compare the competitors across 3-4 parameters that matter most to success of your product – e.g., potency, bioavailability, target product profile alignment, accuracy, sensitivity, ease-of-use, etc.. Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide7. Launched in market Competitive landscape – launched and in development Adjust the placement of tags to reflect actual/expected launch of applicant and competitor products Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project. Launched in market In development<br>
slide8. Project plan (Gantt Chart) Replace with final project plan gantt chart (screenshot/table) in space provided here Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide9. Project plan What does the project plan to do with PRIP support (Most critical 3-4 activities & est. funding required for each) State the target outcome under the PRIP scheme (e.g., clinical validation, manufacturing license etc.)
Develop / scale / clinically validate the solution to reach [target TRL 6/7]
Execute [preclinical studies / tooling & production validation / biosafety approvals]
Co-develop research protocols with [e.g., NIPER Guwahati on phytopharma standardization]
Build internal capability: hiring [XX] scientists, YY support staff focused on [roles: formulation, regulatory, data science] Please describe the most critical 3 activities; challenges expected and plan of action XX Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide10. Implementation Strategy Describe the implementation strategy for three activities to be undertaken internally Activity 1 - XX (E.g- Pre-Clinical Testing)
Description –YY (E.g- Build facility with XX capability and hire YY experts to conduct pre-clinical studies)
Description –YY (E.g- Develop animal study protocols, in-vitro testing models)
Activity 2 – XX (E.g- Phase 1 trial)
Description –YY (E.g- Recruit XX patients from YY indication for conducting ZZ weeks long clinical trials)
Description –YY (E.g- Partner with XX academic or research institutes to serve as clinical trial sites)
Activity 3 – XX (E.g- Regulatory Filings)
Description –YY (E.g- Engage XX regulatory experts to assist with regulatory filings ) Describe the implementation strategy for the three most critical activities planned to be outsourced Activity 1 - XX (E.g- Pre-Clinical Testing)
Description –YY (E.g- Leverage XX facilities at CROs to complete YY studies)
Description –YY (Coordinate with XX accredited labs for GLP-compliant testing and validation)
Activity 2 – XX (E.g- Phase 1 trial)
Description –YY (E.g- Over XX months patient recruitment and site monitoring will be managed by external CRO)
Description –YY (E,g- Clinical data management and statistical analysis will be supported by YY partner)
Activity 3 – XX (E.g- Pilot Batch Manufacturing)
Description –YY (E.g- Outsource manufacturing of XX units to CDMO with YY facilitates, completed in ZZ months) Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide11. Academia Collaboration | <Name of Academia> (if applicable) Partner & Scope Name & Department/Affiliation of Academic Partner :
Name & credentials of Lead PI at Academia:
Why this partner: [Unique capability, facilities, prior data, domain fit] Roles, responsibilities and nature of collaboration Describe role and responsibilities of Academia in collaboration (if applicable)
Describe IP being in-licensed from Academia with actual or estimated cost of In-licensing (if applicable)
Describe plans to transfer/built R&D capability at Academia (if applicable) Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project. Summary of Academic collaboration<br>
slide12. Intellectual Property Status & Strategy Intellectual property (IP) status & freedom to operate (FTO) summary (if applicable) “The asset is protected by [X] Indian and [Y] international patents (e.g., India App No. 20231124567, filed July 2023).”
“Key claims cover: [mechanism / formulation / device sub-component].”
“Patent ownership lies with: [Company / Academic partner / Joint].”
"If licensed: IP in-licensed from [ABC Institute] under Agreement #123.”
“A structured FTO search was conducted in [Month, Year] using [WIPO / Derwent / internal counsel], and found No active infringement risks were identified across US, EU, and Indian markets.” Future IP Strategy (if applicable) "Filing of PCT route expected by [timeline]"
"Additionally, Filing of PCT route expected by [timeline]" Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide13. Regulatory & Quality pathway Regulatory pathway identification (if applicable) “Product classified as a [new drug / phytopharmaceutical / biosimilar / Class C device] under CDSCO/MoHFW definitions.”
“Target regulatory agency: [CDSCO / DCGI / ICMR / BIS / NABL].”
“Planned submission: [CT-New / NDAC / 510(k) / CE-IVDR / Schedule Y] by Q3 FY26.” Status of regulatory and ethics approvals (if applicable) “Regulatory clearance status:
Pre-IND meeting: Scheduled / Completed (Month)
Institutional Biosafety: Filed / Approved / Not required
IEC approval for animal/human studies: Approved by XYZ IEC (Ref #ABC123)” Quality systems & risk management (if applicable) “GLP/ISO 13485/QMS protocols adopted for R&D and pilot manufacturing.”
“Batch records will be maintained as per CDSCO / NABL protocol.”
“Risk classifications aligned to GSPR / India Schedule M for early trial batch design.” Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide14. About <Company Name> & Team Structure Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Placeholder for image, Name, and Designation Please use the space to describe team structure with key personnels in charge. Include placeholders for key OPEN positions Experience of working in the domain/area of the R&D project submitted in PRIP across functions such as research, IPR, fund raising etc. counts as relevant experience
Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide15. Team credentials Experience of working in the domain/area of the R&D project submitted in PRIP across functions such as research, IPR, fund raising etc. counts as relevant experience
Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide16. Project Budget (Add screenshot of the excel template) Replace with final project budget (screenshot/table) in space provided here<br>
slide17. Benefit share & additional support requested from PRIP Selected benefit-share option and projected period of realization Fixed rate option; OR Tiered rate option; OR Equity option (CCPS Share allotment)
“Additional public-good value: Access pledge: Pre-clinical data to be open-sourced for xx; Import substitution by local manufacturing in MedTech cluster of xx; YY job creation..” Other prip support requested / leveraged Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide18. External funding received/raised for project so far Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide19. Appendix Optional Slides (Not more than 2)<br>
slide20. Slide 1 - Optional Use the slide of any additional information, data etc. needed during the presentation Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>
slide21. Slide 2 - Optional Use the slide of any additional information, data etc. needed during the presentation Highly sensitive when filled. Applicants may, at their discretion, choose to redact any information that they deem confidential. Text is grey is suggestive in nature and must be replaced with information relevant to your project.<br>